NEOS2 Score: A Precision Tool for Predicting Treatment Response and Three-Year Functional Recovery in Anti-NMDAR Encephalitis

Introduction: The Evolution of Prognostication in Anti-NMDAR Encephalitis

Anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis remains one of the most significant discoveries in neuroimmunology of the 21st century. While the disease is often devastating—characterized by psychiatric symptoms, cognitive decline, seizures, and autonomic instability—it is also remarkably responsive to immunotherapy. However, the clinical course is notoriously heterogeneous. Some patients achieve full recovery within months, while others face prolonged intensive care stays and permanent disability.

For years, clinicians relied on the original NEOS (anti-NMDAR Encephalitis One-year functional Status) score to estimate recovery. While useful, the clinical landscape has evolved, demanding more nuanced tools that can predict not just one-year disability, but also immediate response to treatment and long-term reintegration into society. The recently published NEOS2 study, an international cohort analysis, provides a sophisticated update to this prognostic framework, offering a validated model for the modern era of autoimmune neurology.